Sort
261,768 grants matching “gene therapy”
Discovery and validation of novel targets for pharmacotherapy of alcoholism
$3,203,547Markus Heilig · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2012 · AA
PRISM: Ethically-guided multimodal AI models for predicting disease pathogenesis in individuals with pathogenic variants
$3,203,253Konrad Karczewski · Massachusetts General Hospital · UG3 · FY2025 · HG
Mechanisms of Fecal Microbiota Transplant Protection from Recurrent C. difficile
$3,202,592William A Petri · University Of Virginia · R01 · FY2025 · AI
Investigating Extrachromosomal DNA (ecDNA) Segregation and Repair in Cancer
$3,201,530Agnel Sfeir · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy
$3,201,150Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL
(2 of 2) Genetic Epidemiology of COPD
$3,199,487Edwin K Silverman · Brigham And Women'S Hospital · R01 · FY2015 · HL
Control Mechanisms for Matching ATP Supply and Demand in Heart Mitochondria
$3,198,760Steven Sollott · National Institute On Aging · ZIA · FY2023 · AG
Sleep and Neurodevelopment Service
$3,192,672Ashura Buckley · National Institute Of Mental Health · ZIA · FY2025 · MH
Immunomodulation in AAV gene therapy
$3,192,404Aravind Asokan · Duke University · R01 · FY2025 · AI
Pharmacogenetics of Asthma Treatment
$3,192,109Scott T Weiss · Brigham And Women'S Hospital · U01 · FY2009 · HL
Pharmacogenetics of Asthma Treatment
$3,190,981Scott T Weiss · Brigham And Women'S Hospital · U01 · FY2007 · HL
The Contribution of Kidney Disease to Age-Associated Cognitive Decline
$3,189,011Pamela Anne Maher · Salk Institute For Biological Studies · RF1 · FY2019 · AG
Immune Pathophysiology of Aplastic Anemia and Immunosuppressive Treatments
$3,187,485Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2016 · HL
Genomics of Acute Myelogenous Leukemia
$3,185,249Timothy J Ley · Washington University · P01 · FY2012 · CA
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial in patients with retinitis pigmentosa
$3,183,918Xiangrong Kong · Johns Hopkins University · UG1 · FY2025 · EY
Centrosome Regulation in Development and Dysregulation in Disease
$3,180,053Nasser Rusan · National Heart, Lung, And Blood Institute · ZIA · FY2025 · HL
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
$3,179,642University Of California San Diego · P01 · FY2001 · CA
The role of microbiota in aging and Alzheimer's disease
$3,179,376Howard L Weiner · Brigham And Women'S Hospital · RF1 · FY2020 · AG
Mitochondrial stress responses in neurodegeneration
$3,176,786Derek Narendra · National Institute Of Neurological Disorders And Stroke · ZIA · FY2024 · NS
AMP-Kinase as a target for neuroprotection in AD
$3,175,735Michael K Lee · University Of Minnesota · RF1 · FY2019 · AG
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making
$3,174,635Diego A. Pizzagalli · Mclean Hospital · P50 · FY2021 · MH
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)
$3,174,487Joel Moss · National Heart, Lung, And Blood Institute · ZIA · FY2012 · HL
Peripherally-restricted non-addictive cannabinoids for cancer pain treatment
$3,174,343Igor Spigelman · University Of California Los Angeles · UG3 · FY2023 · NS
UCSD Alzheimer's Disease Research Center P50
$3,174,023Douglas R Galasko · University Of California, San Diego · P50 · FY2014 · AG
MSUT2 modulates pathological tau in AD and model organisms
$3,173,979Brian C. Kraemer · Seattle Inst For Biomedical/Clinical Res · RF1 · FY2017 · AG